Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Name: Kaimen Rigor review — Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
Item: Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
Rating: 59
Author: Alpha1

Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, Yao W, Zhuang W, Fan Y, Zhuo M, Luo Y, Zhang Z, Song X, Yang R, Yang J, Jin X, Diao Y, Ge J, Zhang L.

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, Yao W, Zhuang W, Fan Y, Zhuo M, Luo Y, Zhang Z, Song X, Yang R, Yang J, Jin X, Diao Y, Ge J, Zhang L.

Read full text (PMC)

DOI

10.1136/bmj-2025-085680

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/8fe57e33-804a-448e-90aa-8aa21c75f115" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/8fe57e33-804a-448e-90aa-8aa21c75f115/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Sacituzumab tirumotecan versus docetaxel for previously treated &amp;lt;i&amp;gt;EGFR&amp;lt;/i&amp;gt;-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

b357a9252e8515db7371f576263491feff3c700189797fe25dc350c262213cc7

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, Yao W, Zhuang W, Fan Y, Zhuo M, Luo Y, Zhang Z, Song X, Yang R, Yang J, Jin X, Diao Y, Ge J, Zhang L.

Paper source

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
Primary endpoint is objective response rate (ORR), a surrogate biomarker. No target engagement data at the tested dose is provided, and no validated evidence linking ORR to clinical outcome (e.g., overall survival) in this specific patient population is cited.
“The primary endpoint was objective response rate as assessed by a blinded independent review committee.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 304DisclosureReporting gaps 05AvailabilityNone found 106CopyeditCopyediting

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed and transparently reported phase 2 randomised controlled trial with strong methods, ethics documentation, and registration. The main weaknesses are reporting-level: several key p-values are printed only as thresholds, the analysis code is not in a version-controlled repository with a DOI, a CONSORT checklist is not referenced, and the docetaxel comparator's manufacturer is not stated.

Both reviewers converged on 7 of 8 dimensions; the key resources divergence (warn vs pass) was resolved to pass because both investigational products are fully dosed, with the docetaxel manufacturer omission preserved as a caveat. Statistics verification covered only the 7 recomputable tests (6 consistent, 0 errors); threshold-only p-values and RPSFT could not be machine-verified. No retracted or unresolvable references, no unsupported claims, and no dead data/code links were found.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Data/code availability incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 3 warn

The introduction cites the epidemiology of EGFR-mutated NSCLC, the mechanism of the novel ADC (increased internalisation with EGFR mutations), and prior phase 1/2 activity. It explicitly discusses why prior phase 3 trials (EVOKE-01, TROPION-Lung01) failed and how this trial's molecularly targeted population addresses those limitations. The hypothesis follows directly from this evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper establishes a clear scientific foundation: prior work on TROP-2-directed ADCs, the unmet need in EGFR-mutated NSCLC, and a mechanistic rationale for sac-TMT in this molecularly defined population.

Evidence

paraphrase[Introduction, paragraphs 2-3]

“Two trophoblast cell surface antigen 2 directed antibody-drug conjugates, sacituzumab govitecan and datopotamab deruxtecan, have both shown promising clinical activity in advanced NSCLC in phase 1 and phase 2 trials. However, randomised phase 3 trials ... did not reach statistical significance for overall survival improvement.”

“Notably, EGFR -mutated NSCLC cell lines resistant to tyrosine kinase inhibitors showed an even higher uptake rate of sac-TMT than cells naive to tyrosine kinase inhibitors.”

Introduction ¶4Find in source

paraphrase[Discussion, 'Comparison with other studies']

“Unlike TROPION-Lung01 and EVOKE-01, which enrolled unselected NSCLC populations, this trial focused specifically on EGFR-mutant patients guided by mechanistic evidence of enhanced sac-TMT uptake.”

PASSReviewer 2· 90% conf

The rationale is well established: the unmet need in EGFR-mutated NSCLC after TKI/platinum failure, the biological rationale for targeting TROP2, and the failures of prior TROP2 ADCs are all cited and used to justify the molecularly enriched design.

Evidence

“Mechanistic exploration in a recent study has shown that the presence of EGFR mutations substantially increases the internalisation and lysosomal uptake of sac-TMT.”

Introduction ¶2Find in source

“The EVOKE-01 trial population was heterogeneous, with a low proportion of patients with actionable genomic alterations that were potentially responsive to the corresponding targeted therapies”

DiscussionFind in source

“It is imperative that higher level evidence from randomised controlled trials be obtained in this molecularly targeted population.”

IntroductionFind in source

For a human RCT, the applicable criteria are randomization_method, randomization_unit, blinding_levels, power_analysis, inclusion_exclusion, and outlier_handling (mapped to analysis-population definition). All are reported adequately: SAS-generated stratified block randomisation with centralised randomisation system; open-label stated with a masked BIRC; 85% power calculation with stated effect size and alpha; detailed eligibility; and ITT/full-analysis/safety populations defined. The remaining bench-oriented criteria are not applicable to this design.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous: randomisation method and stratification stated, a priori power calculation given, open-label design with masked BIRC evaluation, and clear analysis populations defined.

Evidence

“An independent statistician generated the 2:1 randomisation schedule using SAS software (version 9.4). A stratified block design was applied, with stratification by brain metastases (yes or no).”

MethodsFind in source

“With a planned enrolment of about 126 patients, the trial had at least 85% power to detect a 25% difference (docetaxel 10%; sac-TMT 35%) in objective response rate at a one sided α of 0.025.”

Statistical analysisFind in source

“The treatment assignment was not masked to investigators and participants, but the central evaluation by a blinded independent review committee (BIRC) was conducted in a masked manner.”

MethodsFind in source

PASSReviewer 2· 90% conf

Randomisation method, patient-level randomisation unit, open-label design with masked BIRC assessment, a priori power calculation, eligibility criteria, and the analysis populations are all clearly described.

Evidence

MethodsFind in source

“The treatment assignment was not masked to investigators and participants, but the central evaluation by a blinded independent review committee (BIRC) was conducted in a masked manner.”

MethodsFind in source

“With a planned enrolment of about 126 patients, the trial had at least 85% power to detect a 25% difference (docetaxel 10%; sac-TMT 35%) in objective response rate at a one sided α of 0.025.”

Statistical analysisFind in source

Sex (44% men, 60/137) and age (median 56 years) are reported in text and Table 1, with ECOG performance status and cancer stage as health measures. Race/ethnicity is effectively single-population (all Chinese, noted in Limitations). Comorbidities are not tabulated, so demographics is only partially adequate; the other applicable items are adequate.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 70% conf

Sex, age, and health status (ECOG, stage) are thoroughly reported in Table 1; demographic breadth is limited because comorbidities and race/ethnicity are only partially described.

Evidence

“44% (60/137) were men”

ResultsFind in source

paraphrase[Results, 'Patients' and Table 1]

“The median age of the study population was 56 years ... ECOG performance status 1 | 76 (84) | 37 (80) | 113 (82)”

“the enrolled patients were all Chinese, which may limit the generalisability of the findings”

LimitationsFind in source

PASSReviewer 2· 65% conf

Sex and age/health status are well reported, but the demographics sub-criterion is only partially met because race/ethnicity and comorbidities are not presented in the baseline table.

Evidence

“44% (60/137) were men”

ResultsFind in source

“The median age of the study population was 56 years”

ResultsFind in source

“the enrolled patients were all Chinese, which may limit the generalisability of the findings”

LimitationsFind in source

All three applicable criteria are adequate: a named ethics body (ethics committee of Sun Yat-sen University Cancer Centre) with a protocol number and date of approval; written informed consent before enrolment; and a named regulatory framework (Declaration of Helsinki, GCP). IACUC is not applicable to a human trial.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical compliance is fully documented: a named ethics committee with protocol number approved the study, written informed consent was obtained, and compliance with the Declaration of Helsinki and GCP is stated.

Evidence

“The study protocol was reviewed and approved by the ethics committee of Sun Yat-sen University Cancer Centre on 14 October 2022 (A2022-175-01) and at each participating centre before initiation.”

EthicsFind in source

“All patients provided written informed consent before enrolment.”

MethodsFind in source

“This study was conducted in accordance with the principles of the Declaration of Helsinki, good clinical practice guidelines, and applicable laws and regulations.”

EthicsFind in source

PASSReviewer 2· 95% conf

A named ethics committee approved the protocol with a protocol number, written informed consent is documented, and compliance with the Declaration of Helsinki and GCP is stated.

Evidence

EthicsFind in source

“All patients provided written informed consent before enrolment.”

MethodsFind in source

“This study was conducted in accordance with the principles of the Declaration of Helsinki, good clinical practice guidelines, and applicable laws and regulations.”

EthicsFind in source

Sac-TMT and docetaxel are both named with complete dose/regimen; sac-TMT is the sponsor's product, but docetaxel's manufacturer/source and formulation are not given. The TROP-2 IHC assay uses monoclonal antibody EPR20043 (protein link provided) by MEDx Translational Medicine. Statistical software (SAS 9.4) and analysis code (supplementary) are identified. Applicable criteria are 1 of 2 adequate.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 60% conf

The investigational products are named with full dosing regimens and SAS is identified with version, but the docetaxel comparator's manufacturer/source and formulation are not specified, and the IHC antibody is only partially identified.

Evidence

paraphrase[Methods, 'Interventions']

“Sac-TMT was administered intravenously at 5 mg/kg on days 1 and 15 of each four week cycle ... Docetaxel was administered intravenously at a dose of 75 mg/m 2 every three weeks”

“All statistical analyses were conducted using SAS software (version 9.4).”

Statistical analysisFind in source

absence[Methods, 'Interventions']

Docetaxel manufacturer/source and formulation not specified

PASSReviewer 2· 70% conf

The investigational products (sac-TMT and docetaxel) are named with doses and regimens, and the statistical software is identified; the bench-oriented resource criteria are not applicable to this drug trial.

Evidence

“Sac-TMT was administered intravenously at 5 mg/kg on days 1 and 15 of each four week cycle.”

MethodsFind in source

“Docetaxel was administered intravenously at a dose of 75 mg/m 2 every three weeks, on day 1 of each cycle.”

MethodsFind in source

“All statistical analyses were conducted using SAS software (version 9.4).”

Statistical analysisFind in source

Tests are named (CMH, stratified log-rank, Cox, Kaplan-Meier, Clopper-Pearson), assumptions are handled by design (Cox with Efron tie handling, prespecified RPSFT assumption), effect sizes with 95% CIs are reported throughout, SAS 9.4 is identified, and data presentation follows the clinical idiom. Verified arithmetic: all baseline and safety percentages recompute correctly (e.g., 41/91=45%, 51/91=56%, all Table 1 percentages reconcile). The exact_p_values sub-criterion is only partially met because the primary ORR and PFS comparisons are printed as 'one sided P<0.001' rather than exact values (OS is reported exactly as P=0.007). Per the scoring rule, imprecise (threshold) p-value reporting warrants a warn even though no errors are present.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 60% conf

Statistical methods are fully named with effect sizes and 95% CIs, and all tabulated percentages are arithmetically consistent, but several p-values are printed only as thresholds ('one sided P<0.001') rather than exact values.

Evidence

“Treatment groups were compared using the Cochran-Mantel-Haenszel test, stratified by the presence of brain metastases.”

Statistical analysisFind in source

“with a difference of 29% (95% confidence interval (CI) 15% to 43%; one sided P<0.001)”

AbstractFind in source

“hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001”

ResultsFind in source

WARNReviewer 2· 70% conf

Statistical methods, effect sizes with CIs, software, and data presentation are excellent, and all arithmetic checks pass, but several key p-values are reported only as thresholds ('one sided P<0.001') rather than exact values.

Evidence

“Treatment groups were compared using the Cochran-Mantel-Haenszel test, stratified by the presence of brain metastases.”

Statistical analysisFind in source

“with a difference of 29% (95% CI 15% to 43%; one sided P<0.001)”

ResultsFind in source

“hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001”

ResultsFind in source

The data-availability statement names a concrete public repository (Mendeley URL), which is adequate. However, the code is provided only as supplementary files rather than a version-controlled public repository with a permanent identifier, and no DOI/accession is given for the dataset. Accession numbers are not applicable (no sequencing data). 1-2 of 3 applicable criteria are adequate.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositINADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

A concrete data-availability statement points to an open Mendeley dataset, but the analysis code is only in supplementary files and the dataset lacks an explicit DOI/accession.

Evidence

“The data underlying the findings in this paper are openly and publicly available and can be found at https://data.mendeley.com/datasets/hts8z9mx4w/1”

Data availabilityFind in source

“The code used to analyse the data in the paper can be found in the supplementary files.”

Data availabilityFind in source

absence[Data availability statement]

No DOI/accession is stated for the dataset

WARNReviewer 2· 70% conf

The data availability statement is concrete (open Mendeley dataset with URL), but the analysis code is only placed in supplementary files rather than a version-controlled public repository with a persistent identifier.

Evidence

“The data underlying the findings in this paper are openly and publicly available and can be found at https://data.mendeley.com/datasets/hts8z9mx4w/1”

Data availabilityFind in source

“The code used to analyse the data in the paper can be found in the supplementary files.”

Data availabilityFind in source

The trial is registered (NCT05631262), methods are detailed enough for replication, all outcomes (ORR, DCR, PFS, TTR, DOR, OS, safety) are reported including a null biomarker finding, and limitations (sample size, single-country, surrogate primary endpoint, no QoL) are discussed. A CONSORT checklist is not referenced, though a trial-profile figure is present. Funding and ICMJE COI disclosures are complete.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Reporting is complete and transparent: trial registered, methods detailed, all pre-specified endpoints reported, limitations explicitly discussed, and funding/COI statements provided; only an explicit CONSORT checklist reference is absent.

Evidence

“Trial registration ClinicalTrials.gov NCT05631262”

AbstractFind in source

“Although the modest sample size was appropriate for this phase 2 trial, the enrolled patients were all Chinese, which may limit the generalisability of the findings.”

LimitationsFind in source

“This study was funded by Sichuan Kelun-Biotech Biopharmaceutical and partly supported by the National Natural Science Foundation of China”

FundingFind in source

PASSReviewer 2· 80% conf

Methods are detailed, the trial is registered with a number, outcomes are fully reported, limitations and funding/COI are disclosed, and conclusions are proportional to the evidence.

Evidence

“ClinicalTrials.gov NCT05631262”

AbstractFind in source

“Although the modest sample size was appropriate for this phase 2 trial, the enrolled patients were all Chinese, which may limit the generalisability of the findings.”

LimitationsFind in source

“This study was funded by Sichuan Kelun-Biotech Biopharmaceutical and partly supported by the National Natural Science Foundation of China”

FundingFind in source

Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 29 references by DOI: 29 verified.

1 data/code link checked; 1 live.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

4 copyedit issues flagged (1 major): mostly punctuation, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and internally consistent; no validity threats warrant retraction. An informed reader should weigh the reporting gaps — exact p-values for ORR/PFS, code availability in a permanent repository, and the missing CONSORT checklist — as minor transparency issues that would justify a correction or erratum, and should interpret the single-country phase 2 design and the baseline EGFR-mutation imbalance as interpretative caveats.

1.
HIGHstatistics
Report the exact p-values for the primary ORR comparison and the PFS comparison (currently printed only as 'one sided P<0.001') in the Abstract and Results/'Efficacy' sections.
Threshold-only p-values for primary endpoints are imprecise reporting and prevent readers and meta-analysts from assessing the exact strength of evidence.
2.
HIGHcopyedit
Fix the author byline so names and academic titles are separated (e.g., 'Wenfeng Fang, professor; Xingya Li, professor; ...') on the title page.
The run-together names and titles make authorship attribution hard to parse and would be flagged by a copyeditor or reader.
3.
MEDIUMdata code
Deposit the analysis code in a version-controlled public repository with a persistent DOI (e.g., Zenodo or a GitHub release) and update the Data availability statement to point to it.
Code confined to supplementary files lacks a permanent identifier, limiting reproducibility and long-term access.
4.
MEDIUMcopyedit
Remove the duplicated data-availability statement and supplementary-materials list that repeat earlier sections at the end of the article.
Duplicated reporting blocks are confusing and should be consolidated into a single statement.
5.
MEDIUMreporting
Reference the CONSORT reporting checklist in the Methods (or add a completed checklist to the supplementary appendix).
A CONSORT reference is expected for a randomised trial and closes the only reporting-transparency gap identified.
6.
LOWreporting
Add race/ethnicity and relevant comorbidity detail to Table 1 or a supplementary baseline table.
The demographics sub-criterion is only partially met because these baseline characteristics are not tabulated.
7.
LOWrigor
State the manufacturer and formulation/strength of the docetaxel comparator in the Interventions section.
Full identification of the comparator supports replication; the current dosing information is adequate but the source is unspecified.
8.
LOWcopyedit
Clean the stray duplicated article identifier 'e085680' in the header/journal metadata before the Abstract.
The duplicated identifier is a rendering artifact that should be removed for a clean published record.
9.
LOWrigor
In the Discussion, explicitly address the potential confounding effect of the baseline EGFR-mutation imbalance (Exon 19 deletion 47% sac-TMT vs 70% docetaxel) on the efficacy estimates.
The acknowledged imbalance is a potential confounder for the observed efficacy differences and deserves an explicit sensitivity or interpretive statement.

Full text (52,039 chars)Analyzed: Aug 10, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, Yao W, Zhuang W, Fan Y, Zhuo M, Luo Y, Zhang Z, Song X, Yang R, Yang J, Jin X, Diao Y, Ge J, Zhang L.

Read full text (PMC)

DOI

10.1136/bmj-2025-085680

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/8fe57e33-804a-448e-90aa-8aa21c75f115" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/8fe57e33-804a-448e-90aa-8aa21c75f115/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Sacituzumab tirumotecan versus docetaxel for previously treated &amp;lt;i&amp;gt;EGFR&amp;lt;/i&amp;gt;-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

b357a9252e8515db7371f576263491feff3c700189797fe25dc350c262213cc7

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
Primary endpoint is objective response rate (ORR), a surrogate biomarker. No target engagement data at the tested dose is provided, and no validated evidence linking ORR to clinical outcome (e.g., overall survival) in this specific patient population is cited.
“The primary endpoint was objective response rate as assessed by a blinded independent review committee.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 304DisclosureReporting gaps 05AvailabilityNone found 106CopyeditCopyediting

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

3 findings · worst high

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Data/code availability incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 3 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

paraphrase[Introduction, paragraphs 2-3]

“Notably, EGFR -mutated NSCLC cell lines resistant to tyrosine kinase inhibitors showed an even higher uptake rate of sac-TMT than cells naive to tyrosine kinase inhibitors.”

Introduction ¶4Find in source

paraphrase[Discussion, 'Comparison with other studies']

PASSReviewer 2· 90% conf

Evidence

“Mechanistic exploration in a recent study has shown that the presence of EGFR mutations substantially increases the internalisation and lysosomal uptake of sac-TMT.”

Introduction ¶2Find in source

“The EVOKE-01 trial population was heterogeneous, with a low proportion of patients with actionable genomic alterations that were potentially responsive to the corresponding targeted therapies”

DiscussionFind in source

“It is imperative that higher level evidence from randomised controlled trials be obtained in this molecularly targeted population.”

IntroductionFind in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous: randomisation method and stratification stated, a priori power calculation given, open-label design with masked BIRC evaluation, and clear analysis populations defined.

Evidence

MethodsFind in source

“With a planned enrolment of about 126 patients, the trial had at least 85% power to detect a 25% difference (docetaxel 10%; sac-TMT 35%) in objective response rate at a one sided α of 0.025.”

Statistical analysisFind in source

“The treatment assignment was not masked to investigators and participants, but the central evaluation by a blinded independent review committee (BIRC) was conducted in a masked manner.”

MethodsFind in source

PASSReviewer 2· 90% conf

Evidence

MethodsFind in source

“The treatment assignment was not masked to investigators and participants, but the central evaluation by a blinded independent review committee (BIRC) was conducted in a masked manner.”

MethodsFind in source

“With a planned enrolment of about 126 patients, the trial had at least 85% power to detect a 25% difference (docetaxel 10%; sac-TMT 35%) in objective response rate at a one sided α of 0.025.”

Statistical analysisFind in source

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 70% conf

Sex, age, and health status (ECOG, stage) are thoroughly reported in Table 1; demographic breadth is limited because comorbidities and race/ethnicity are only partially described.

Evidence

“44% (60/137) were men”

ResultsFind in source

paraphrase[Results, 'Patients' and Table 1]

“The median age of the study population was 56 years ... ECOG performance status 1 | 76 (84) | 37 (80) | 113 (82)”

“the enrolled patients were all Chinese, which may limit the generalisability of the findings”

LimitationsFind in source

PASSReviewer 2· 65% conf

Sex and age/health status are well reported, but the demographics sub-criterion is only partially met because race/ethnicity and comorbidities are not presented in the baseline table.

Evidence

“44% (60/137) were men”

ResultsFind in source

“The median age of the study population was 56 years”

ResultsFind in source

“the enrolled patients were all Chinese, which may limit the generalisability of the findings”

LimitationsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

EthicsFind in source

“All patients provided written informed consent before enrolment.”

MethodsFind in source

“This study was conducted in accordance with the principles of the Declaration of Helsinki, good clinical practice guidelines, and applicable laws and regulations.”

EthicsFind in source

PASSReviewer 2· 95% conf

A named ethics committee approved the protocol with a protocol number, written informed consent is documented, and compliance with the Declaration of Helsinki and GCP is stated.

Evidence

EthicsFind in source

“All patients provided written informed consent before enrolment.”

MethodsFind in source

“This study was conducted in accordance with the principles of the Declaration of Helsinki, good clinical practice guidelines, and applicable laws and regulations.”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 60% conf

Evidence

paraphrase[Methods, 'Interventions']

“Sac-TMT was administered intravenously at 5 mg/kg on days 1 and 15 of each four week cycle ... Docetaxel was administered intravenously at a dose of 75 mg/m 2 every three weeks”

“All statistical analyses were conducted using SAS software (version 9.4).”

Statistical analysisFind in source

absence[Methods, 'Interventions']

Docetaxel manufacturer/source and formulation not specified

PASSReviewer 2· 70% conf

Evidence

“Sac-TMT was administered intravenously at 5 mg/kg on days 1 and 15 of each four week cycle.”

MethodsFind in source

“Docetaxel was administered intravenously at a dose of 75 mg/m 2 every three weeks, on day 1 of each cycle.”

MethodsFind in source

“All statistical analyses were conducted using SAS software (version 9.4).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 60% conf

Evidence

“Treatment groups were compared using the Cochran-Mantel-Haenszel test, stratified by the presence of brain metastases.”

Statistical analysisFind in source

“with a difference of 29% (95% confidence interval (CI) 15% to 43%; one sided P<0.001)”

AbstractFind in source

“hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001”

ResultsFind in source

WARNReviewer 2· 70% conf

Evidence

“Treatment groups were compared using the Cochran-Mantel-Haenszel test, stratified by the presence of brain metastases.”

Statistical analysisFind in source

“with a difference of 29% (95% CI 15% to 43%; one sided P<0.001)”

ResultsFind in source

“hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001”

ResultsFind in source

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositINADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

A concrete data-availability statement points to an open Mendeley dataset, but the analysis code is only in supplementary files and the dataset lacks an explicit DOI/accession.

Evidence

“The data underlying the findings in this paper are openly and publicly available and can be found at https://data.mendeley.com/datasets/hts8z9mx4w/1”

Data availabilityFind in source

“The code used to analyse the data in the paper can be found in the supplementary files.”

Data availabilityFind in source

absence[Data availability statement]

No DOI/accession is stated for the dataset

WARNReviewer 2· 70% conf

Evidence

“The data underlying the findings in this paper are openly and publicly available and can be found at https://data.mendeley.com/datasets/hts8z9mx4w/1”

Data availabilityFind in source

“The code used to analyse the data in the paper can be found in the supplementary files.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

“Trial registration ClinicalTrials.gov NCT05631262”

AbstractFind in source

“Although the modest sample size was appropriate for this phase 2 trial, the enrolled patients were all Chinese, which may limit the generalisability of the findings.”

LimitationsFind in source

“This study was funded by Sichuan Kelun-Biotech Biopharmaceutical and partly supported by the National Natural Science Foundation of China”

FundingFind in source

PASSReviewer 2· 80% conf

Methods are detailed, the trial is registered with a number, outcomes are fully reported, limitations and funding/COI are disclosed, and conclusions are proportional to the evidence.

Evidence

“ClinicalTrials.gov NCT05631262”

AbstractFind in source

“Although the modest sample size was appropriate for this phase 2 trial, the enrolled patients were all Chinese, which may limit the generalisability of the findings.”

LimitationsFind in source

“This study was funded by Sichuan Kelun-Biotech Biopharmaceutical and partly supported by the National Natural Science Foundation of China”

FundingFind in source

Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 29 references by DOI: 29 verified.

1 data/code link checked; 1 live.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

4 copyedit issues flagged (1 major): mostly punctuation, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHstatistics
Report the exact p-values for the primary ORR comparison and the PFS comparison (currently printed only as 'one sided P<0.001') in the Abstract and Results/'Efficacy' sections.
Threshold-only p-values for primary endpoints are imprecise reporting and prevent readers and meta-analysts from assessing the exact strength of evidence.
2.
HIGHcopyedit
Fix the author byline so names and academic titles are separated (e.g., 'Wenfeng Fang, professor; Xingya Li, professor; ...') on the title page.
The run-together names and titles make authorship attribution hard to parse and would be flagged by a copyeditor or reader.
3.
MEDIUMdata code
Deposit the analysis code in a version-controlled public repository with a persistent DOI (e.g., Zenodo or a GitHub release) and update the Data availability statement to point to it.
Code confined to supplementary files lacks a permanent identifier, limiting reproducibility and long-term access.
4.
MEDIUMcopyedit
Remove the duplicated data-availability statement and supplementary-materials list that repeat earlier sections at the end of the article.
Duplicated reporting blocks are confusing and should be consolidated into a single statement.
5.
MEDIUMreporting
Reference the CONSORT reporting checklist in the Methods (or add a completed checklist to the supplementary appendix).
A CONSORT reference is expected for a randomised trial and closes the only reporting-transparency gap identified.
6.
LOWreporting
Add race/ethnicity and relevant comorbidity detail to Table 1 or a supplementary baseline table.
The demographics sub-criterion is only partially met because these baseline characteristics are not tabulated.
7.
LOWrigor
State the manufacturer and formulation/strength of the docetaxel comparator in the Interventions section.
Full identification of the comparator supports replication; the current dosing information is adequate but the source is unspecified.
8.
LOWcopyedit
Clean the stray duplicated article identifier 'e085680' in the header/journal metadata before the Abstract.
The duplicated identifier is a rendering artifact that should be removed for a clean published record.
9.
LOWrigor
In the Discussion, explicitly address the potential confounding effect of the baseline EGFR-mutation imbalance (Exon 19 deletion 47% sac-TMT vs 70% docetaxel) on the efficacy estimates.
The acknowledged imbalance is a potential confounder for the observed efficacy differences and deserves an explicit sensitivity or interpretive statement.

Full text (52,039 chars)Analyzed: Aug 10, 2026